



OPEN

## Impact of porcine cytomegalovirus on long-term orthotopic cardiac xenotransplant survival

Joachim Denner<sup>1,9</sup>✉, Matthias Längin<sup>2,3,9</sup>, Bruno Reichart<sup>3</sup>, Luise Krüger<sup>1</sup>, Uwe Fiebig<sup>1</sup>, Maren Mokolke<sup>3</sup>, Julia Radan<sup>3</sup>, Tanja Mayr<sup>2</sup>, Anastasia Milusev<sup>4</sup>, Fabian Luther<sup>4</sup>, Nicoletta Sorvillo<sup>4</sup>, Robert Rieben<sup>4</sup>, Paolo Brenner<sup>5</sup>, Christoph Walz<sup>6</sup>, Eckhard Wolf<sup>7</sup>, Berit Roshani<sup>8</sup>, Christiane Stahl-Hennig<sup>8</sup> & Jan-Michael Abicht<sup>2,3</sup>

Xenotransplantation using pig organs has achieved survival times up to 195 days in pig orthotopic heart transplantation into baboons. Here we demonstrate that in addition to an improved immunosuppressive regimen, non-ischæmic preservation with continuous perfusion and control of post-transplantation growth of the transplant, prevention of transmission of the porcine cytomegalovirus (PCMV) plays an important role in achieving long survival times. For the first time we demonstrate that PCMV transmission in orthotopic pig heart xenotransplantation was associated with a reduced survival time of the transplant and increased levels of IL-6 and TNF $\alpha$  were found in the transplanted baboon. Furthermore, high levels of tPA-PAI-1 complexes were found, suggesting a complete loss of the pro-fibrinolytic properties of the endothelial cells. These data show that PCMV has an important impact on transplant survival and call for elimination of PCMV from donor pigs.

Recently, consistent success in life-supporting (orthotopic) porcine cardiac xenotransplantation has been reported<sup>1</sup>. In that study hearts from  $\alpha$ 1,3-galactosyltransferase-knockout (GTKO) pigs that express human membrane cofactor protein (CD46) and human thrombomodulin (hTM) had been transplanted into baboons and survival times up to 195 days were achieved. This is a milestone on the way to clinical cardiac xenotransplantation which is urgently needed: The supply of human organs does not match the needs and many patients with terminal cardiac failure die while being on the waiting list.

Xenotransplantation with genetically modified porcine organs, as an alternative to allogenic (human-to-human) procedures may be associated with the transmission of porcine microorganisms, among them the porcine endogenous retroviruses (PERVs). PERVs are integrated in the genome of all pigs and they are able to infect human cells<sup>2</sup>. However, until now no PERV transmission was observed in the first preclinical (for review see ref.<sup>2</sup>) and clinical xenotransplantation trials<sup>3,4</sup>. Whereas PERV-A and PERV-B, which are present in all pigs, infect human cells, PERV-C infects only pig cells and is not present in all pigs<sup>2</sup>. However, recombinations between PERV-A and PERV-C can occur and the recombinant PERV-A/C is characterised by a higher replication competence<sup>5</sup>. Therefore, it is highly recommended to use PERV-C-free pigs for xenotransplantation. Interestingly, using CRISPR/Cas all retroviral sequences can be inactivated in the pig genome<sup>7</sup>, however, it is still unclear whether this is needed for a safe xenotransplantation<sup>9</sup>.

From the other viruses widely distributed in pigs, the porcine cytomegalovirus (PCMV) is of great concern<sup>10</sup>. PCMV is related with the human cytomegalovirus (HCMV), also called human herpesvirus 5 (HHV-5). HCMV causes fatal infections in human organ transplant recipients if not treated, leading to end-organ disease, such as gastrointestinal ulceration, hepatitis, pneumonitis or retinitis. HCMV can also lead to systemic infection and disease once a threshold value of virus load is exceeded<sup>11</sup>. In fact, HCMV has also been detected in the bowel mucosa where its reactivation has been suggested to lead to IL-6 release and inflammatory bowel disease<sup>12</sup>.

<sup>1</sup>Robert Koch Institute, Berlin, Germany. <sup>2</sup>Department of Anaesthesiology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany. <sup>3</sup>Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilians-Universität München, Munich, Germany. <sup>4</sup>Department of Biomedical Research (DMBR), University of Bern, Bern, Switzerland. <sup>5</sup>Department of Cardiac Surgery, University Hospital, Maximilians-Universität München, Munich, Germany. <sup>6</sup>Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany. <sup>7</sup>Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, Ludwig-Maximilians-Universität München, Munich, Germany. <sup>8</sup>Unit of Infection Models, German Primate Center, Göttingen, Germany. <sup>9</sup>These authors contributed equally: Joachim Denner and Matthias Längin. ✉email: DennerJ@rki.de

Animal number	ID number	Group <sup>a</sup>	PCMV in the explanted heart (copies per reaction)	Survival time (days)
A (1) <sup>b</sup>	16,752	I	368	3
B (2)	16,754	I	30	1
C (3)	16,755	I	1.940.000 <sup>c</sup>	30
D (4)	16,751	I	32	1
E (5)	16,753	I	62	1
F (6)	16,048	II	839.000	18
G (7)	17,138	II	0 <sup>d</sup>	4
H (8)	17,140	II	39.200	27
I (9)	17,139	II	2.950.000 <sup>c</sup>	40
P	17,494	III	33.000.000	15
Q	17,492	III	15.350.99	27

**Table 1.** PCMV infection in explanted pig hearts from different baboons. <sup>a</sup>Treatment groups according to Längin et al. 2019. <sup>b</sup>In brackets animal number as in Längin et al. 2019<sup>1</sup>. <sup>c</sup>PCMV was also detected in the blood and the serum of baboon C ( $3 \times 10^4$  genome equivalent/ml blood) (Morozov et al., 2016, baboon 57)<sup>26</sup>. <sup>d</sup>No PCMV was found in different organs of baboon G (Fiebig et al. 2018, baboon 62)<sup>27</sup>. <sup>e</sup>PCMV was found in the spleen, liver, kidney, blood of baboon I (between 100 and 10,000 copies / 100 ng DNA) (Fiebig et al., 2018, baboon 64)<sup>27</sup>.

Meanwhile it was shown that PCMV is a roseolovirus and more closely related with human herpesviruses 6A, 6B and 7 (HHV-6A, HHV-6B, and HHV-7)<sup>13</sup>. Therefore the thermology PCMV is to a certain degree misleading and should actually be porcine roseolovirus (PCMV/PRV)<sup>14</sup>. The International Committee on Taxonomy of Viruses (ICTV) classified this virus as suid betaherpesvirus 2<sup>15</sup>. The closely related HHV-6 and HHV-7 were reported to be associated with numerous diseases, e.g., liver failure<sup>16</sup>, multiple sclerosis<sup>17</sup> and Alzheimer disease<sup>18</sup>. Furthermore, HHV-6 was found to promote cancer development<sup>19</sup> and accelerate acquired immunodeficiency syndrome (AIDS) in humans and monkeys<sup>20,21</sup>, possibly by its immunosuppressive property<sup>21–25</sup>.

Recently, by analysing a baboon recipient of orthotopic pig heart transplantation with a relatively short survival time (29 days) and hepatic failure, PCMV/PRV infection was observed in the recipient<sup>26</sup>. In addition, PCMV/PRV transmission was also found in two other baboon recipients with 4 and 40 days of transplant survival. Immunohistochemical studies of the recipient baboons showed PCMV/PRV-expressing cells in all organs of the animal, most likely representing disseminated pig cells<sup>27</sup>. These data, together with similar data on pig kidney xenotransplants in non-human primates<sup>28,29</sup>, suggest that PCMV/PRV significantly reduces the survival of pig xenotransplants. However, the mechanism through which PCMV/PRV reduces transplant survival is still unclear<sup>30</sup>.

To better understand the impact of PCMV/PRV on pig transplant survival in orthotopic heart transplantation, numerous donor pig—baboon recipient pairs were retrospectively analysed for PCMV/PRV transmission. Here, we demonstrate for the first time that PCMV transmission in orthotopic pig heart xenotransplantation is associated with a reduced survival time of the transplant and indicate an impact of PCMV/PRV on cytokine release and coagulation. Furthermore, we show that other porcine viruses, which could potentially impact xenotransplant survival, including PERVs, hepatitis E virus (HEV), three porcine lymphotropic herpesviruses (PLHV) and the porcine circoviruses (PCV) 1 and 2, had not been transmitted.

## Results

**Transmission of PCMV/PRV into baboons after orthotopic pig heart transplantation.** All baboon recipients received an immunosuppression including an induction therapy with an anti-CD20 antibody, anti-thymocyte-globulin and a monkey-specific anti-CD40 monoclonal antibody or humanized anti-CD40LPA-Sylated as described in detail<sup>1</sup>. Three groups of animals have been transplanted. In group I, donor organs were preserved with two clinically approved crystalloid solutions, the animals survived for less than 30 days (animal C, Table 1) and suffered from perioperative cardiac xenograft dysfunction (PCXD). To reduce the PCXD, in group II the pig hearts were preserved with an oxygenated albumin-containing hyperoncotic cardioplegic solution. Three of the four animals of this group lived for 18 (animal F), 27 (animal H) and 40 (animal I) days. A diastolic heart failure and subsequent congestive liver damage resulting from massive cardiac overgrowth were observed in these animals. To prevent this, in group III baboon recipients were weaned from cortisone at an early stage and received antihypertensive treatment since pigs have a lower systolic blood pressure than baboons. In addition, a temsirolimus medication was used to counteract cardiac overgrowth. Two recipients in this group survived for 195 (animal O, Table 2) and 182 (animal N) days<sup>1</sup>.

When the recipient baboon organs from group I and group II were analysed for PCMV/PRV transmission, PCMV/PRV was detected not only in the explanted pig heart but also in several different organs from all baboons except one (G; Table 1). Some of these animals (B, D, E) survived only one day and showed very low virus load in the explanted heart. However, after only three days an increase of the virus load was observed (animal A). When analysing the animals with the longer survival time, e.g., animal F with 18 days, animal H with 27 days, animal C with 30 days and animal I with 40 days, it became evident that PCMV/PRV replicates over time. Animal I

Animal	ID number	Transplant survival days	PCMV real-time PCR	BaCMV real-time PCR	HEV		PLHV1, 2 PCR	PLHV3 PCR	PERV			PCV1,2 PCR
					ELISA/WB*	Real-time PCR			PERV PCR	PERV-C PCR	WB*	
Pig 5528			–		–	–	++	–	++	+		–
Baboon J	17,186	90	–	+	n.t	–	–	–	+++	–	–	n.t
Pig 5415			–	–	+	–	+++	–	++	+		–
Baboon K	17,187	50	–	+	–	–	–	–	+++	–	–	n.t
Pig 5420			–	–	+	–	+++	–	++	+		–
Baboon L	17,290	90	–	+	–	–	–	–	+++	–	–	n.t
Pig 5623			++		–	–	+	–	++	+		–
Baboon M	17,188	10	++	+++	n.t	–	–	–	+++	–	–	–
Pig 5803			–		–	–	+++	–	++	+		–
Baboon O	17,493	195	–	+	–	–	–	–	+++	–	–	
Pig 5807			–		–	–	+++	–	++	+		–
Baboon N	17,491	182	–	+	–	–	–	–	+++	–	–	–
Pig 6249			++		–	–	+++	–	++	+		–
Baboon P	17,494	15	+++	+	–	–	–	–	+++	–	–	–
Pig 6253			+		–	–	++	–	++	+		–
Baboon Q	17,492	27	++	+	–	–	–	–	+++	–	–	–


**Table 2.** Testing donor pigs and recipient baboons of transplantation group III for different viruses. \*WB, Western blot assay; \*\*indicating microchimerism; n.t., not tested.

(number 64 in publication 27) had not only a very high virus load in the explanted heart, but a high virus load was also found in the spleen, kidney, and blood (between 100 and 1000 copies/100 ng DNA) and cells expressing PCMV/PRV proteins were found in all organs of the transplanted animal<sup>27</sup>. The longer the transplant was present in the recipient the higher was the virus load in the explanted and formalin/ethanol fixed pig heart (Table 1). This rule is operative only to a certain threshold of the virus load, above this threshold the survival time decreases due to the pathogenic effect of the virus.


When the recipient baboons of group III (early cortisone tapering, antihypertensive treatment and temsirolimus) and their donor pigs were analysed, PCMV/PRV was found to be absent in the donor pigs and consequently in the transplanted baboons of animals with the longest survival times such as baboon J (90 days), baboon K (50 days), baboon L (90 days), baboon N (182 days) and baboon O (195 days) (Table 2). In contrast, PCMV/PRV was found in the donor pigs of transplanted baboons that showed a shorter survival rate like baboon P (15 days), baboon Q (27 days) and M (euthanized 10 days after transplantation because of severe iatrogenic complication) (Table 2). In the hearts explanted from animals P and Q astonishingly high copy numbers of PCMV/PRV were detected. Since all these data were obtained testing the formalin/ethanol fixed pig hearts, in addition the virus load in the frozen right ventricle of the heart explanted from baboon P was analysed and 48 million copies were found (33 million in the fixed heart). This is in the same magnitude, indicating that testing of fixed and frozen materials give approximately the same result.

**Distribution of PCMV/PRV in pig and baboon organs.** Using real-time PCR, the copy number (viral load) of PCMV/PRV was analysed in PBMCs and different organs of all donor pigs and in the organs of the transplanted baboons after removal of the transplanted heart, which was also analysed. As an example we illustrate in Fig. 1 the pair donor pig 6249 and the recipient baboon P. All other animals analysed had a similar pattern. The virus load in several organs of baboon I has been shown previously (animal 64 in reference 27). With exception of the skin, the viral load was high in all baboon organs (spleen, liver, muscle, kidney lung and lymph nodes) and donor pig organs (lung, spleen, liver, kidney and PBMCs), in agreement with the results in baboon I<sup>27</sup>. The highest viral load was found in the explanted pig heart (Fig. 1). This is the main place of virus replication and this replication is possible due to the absence of the pig immune system, which could have reacted against the virus in the donor pig, and due to the strong immunosuppression in the baboon inhibiting its immune system.

**Pathological findings and modulation of cytokine release.** As mentioned above, baboons N and O from treatment group III, showed the longest survival time, 182 and 195 days, respectively, compared to baboons P and Q, which survived only 15 and 27 days. Interestingly, both baboons P and Q were characterized by pathological and inflammatory changes, some of which might be the result of a PCMV/PRV infection, bearing in mind the broad disease spectrum induced by herpesviruses. Both animals showed signs of low-output heart failure at the end of the experiments, resulting in multi organ dysfunction as indicated by the pathological increase in functional parameters of liver, pancreas and kidney such as aspartate aminotransferase, creatine kinase, and lactate dehydrogenase. Decreased abdominal perfusion probably caused loss of mucosal barrier function in the gut, leading to translocation of intestinal microbes and to a strong increase of levels of interleukin-6 (IL-6) (Fig. 2). In fact, Klebsiella pneumonia was found in blood cultures of baboon Q one day before euthanasia. The




**Figure 1.** Viral load (copies per 100 ng DNA) in different organs of baboon P after explantation of the pig heart, in PBMCs and different organs of the donor pig and in the pig heart after explantation as measured by real-time PCR.



**Figure 2.** Kinetics of the IL-6 amount in the blood of transplanted baboons as measured by ELISA. The baboon recipients of the treatment group III are indicated (N, O, P, Q).

increase in IL-6 most probably is not due to treatment with an IL-6-receptor antagonist tocilizumab, since treatment began at the very beginning of transplantation and was given to all animals as part of the treatment protocol, including animals N and O that did not show high plasma levels of the cytokine. To confirm these data and to perform a broader analysis of further pro- and anti-inflammatory cytokines, a cytometric bead array (CBA) assay for non-human primate Th1/Th2 cytokines as well as an IL-10 ELISA were performed. The obtained data confirmed the strong increase of IL-6 (Fig. 3A), and also revealed a substantial increase of tumour necrosis factor (TNF) in baboons P and Q with the PCMV/PRV-positive hearts (Fig. 3B). No alterations were observed in serum levels of the proinflammatory cytokines interferon  $\gamma$  (IFN  $\gamma$ ) (Fig. 3C) and interleukin 2 (IL-2) (Fig. 3D) as well as the anti-inflammatory cytokines interleukin-4 (IL-4) (Fig. 3E), interleukin-5 (IL-5) (Fig. 3F), and interleukin-10 (IL-10) (data not shown).

Interestingly, histological examination of the explanted pig hearts from baboons N, O, P, and Q revealed marked perivascular and moderate edema in otherwise unremarkable myocardial tissue (Fig. 4A, B). In particular, no morphologic signs of cellular or antibody-mediated transplant rejection was found (Fig. 4B), and in parallel no elevated levels of non-galactose- $\alpha$ 1,3-galactose reactive IgM and IgG were measured (not shown), indicating that immunological rejection was not the cause of the reduced survival observed in animals P and Q.



**Figure 3.** Increased IL-6 and TNF serum levels in baboons with PCMV/PRV-positive hearts. BD CBA Non-human primate Th1/Th2 kit was used to measure plasma levels of (A) IL-6, (B) TNF, (C) IFN  $\gamma$ , (D) IL-2, (E) IL-4 and (F) IL-5 one week before transplantation (day -7) and during the experiment (day 13, 26, 180 and 194, respectively) in baboons N, O, P and Q. Dotted lines indicate lowest standard concentration.

**High levels of tPA-PAI-1 complex.** To analyse whether animals infected with PCMV/PRV could present alteration in the coagulation system, tissue plasminogen activator (tPA) and plasminogen activator inhibitor 1 complexes (tPA-PAI-1) were measured in plasma samples by an ELISA<sup>31</sup>. Interestingly, we observed that baboons P and Q, which presented clear pathological alterations, also had very high levels of tPA-PAI-1 complexes (Fig. 5). This indicates a hypercoagulable state of the two animals and a decrease in fibrinolysis, originated most probably by endothelial cell damage.


**Expression of BaCMV after PCMV/PRV transmission.** Since all baboon recipients carried BaCMV, we looked into a possible activation of this virus, which may also influence the survival time of the transplant and recipient. Recently a significantly increased expression of BaCMV in plasma of baboon I after transplantation of a PCMV/PRV-positive pig heart was measured<sup>27</sup>. Although analysis of BaCMV in all baboon organs (liver, kidney, spleen and lung) showed a high virus load, a clear and measurable increase of the BaCMV virus load in the blood after transplantation as was found in animal I was not observed (Table 2). Moreover, no differences in the BaCMV viral load in baboons with a long or a short survival time was observed. This highly suggests that activation of BaCMV is not the cause of early loss of the transplanted pig heart.

**Prevalence and transmission of other porcine viruses.** In order to analyse whether other porcine viruses were present in the donor pig and were transmitted to the recipient, which also may influence the survival time of the xenotransplant, both Western blot and PCR/RT-PCR analysis was performed to detect PERV, PLHV, PCV and HEV in both pig and baboon tissues. PLHV-1 and PLHV-2 had been detected in all donor pigs used in this study. Despite this, no transmission of these viruses to the recipient baboons was observed (Table 2). Although Western blot analyses showed HEV infection in the donor pigs of baboons G, I, K and L, detection of HEV by RT-PCR gave negative results in all donor pigs, indicating that the virus was not present in their blood. However, transmission to the recipients was not observed (Table 2). Indeed, all baboons were negative for HEV infection independently to the test used for analysis, e.g., no positive RT-PCR reactions and no positive ELISA or Western blot analyses were found.

PERV was detected as expected in all donor pigs by PCR using specific primers binding to a highly conserved region in the polymerase (pol) gene (Table 2). In fact, these primers recognise both PERV-A, PERV-B and PERV-C. Since PERV-A and PERV-B is present in all pigs<sup>2</sup>, a PCR using primers specific for the env region of PERV-C was performed, and PERV-C was detected in all donor pigs.

PERV was also analysed in baboon samples using the pol specific PCR, detecting PERV-A, PERV-B and PERV-C. As shown in Table 2, these sequences were detected in all baboon blood samples, however the detection of PERV in the blood samples might be due to circulating cellular DNA from dead transplant cells or from circulating pig cells, a phenomenon called microchimerism. This was confirmed by the finding of porcine






**Figure 4.** **A** Histopathologic evaluation of the explanted pig hearts from baboons N to Q. Arrowheads mark perivascular and arrows moderate edema in otherwise unremarkable myocardial tissue in all specimens. Scale bars indicate 250  $\mu\text{m}$ . **B.** Histopathologic evaluation revealed perivascular (arrowhead) and interstitial (arrow) edema in otherwise unremarkable myocardial tissue in all specimens. In particular, no morphologic signs of cellular or antibody-mediated transplant reaction was found. Scale bars indicate 100  $\mu\text{m}$ .

glyceraldehyde-3-phosphat-dehydrogenase (GAPDH) by a specific PCR. Since the copy number of PERV-C in pig cells is much lower compared to the copy number of PERV-A and PERV-B, PERV-C sequences could not be detected in the blood of the baboons. Moreover, Western blot analysis showed no anti-PERV antibodies in all baboon samples, clearly indicating absence of infection (Supplementary Fig. 1). In summary, no other pig viruses which could influence the survival time of the transplant had been transmitted to the recipient baboons.

**Discussion.** Recently, survival times of 182 and 195 days after preclinical orthotopic pig-to-baboon xenotransplantation were achieved by several measures that include an improved immunosuppressive regi-



**Figure 5.** Measurement of tPA-PAI-1 complexes in the blood of baboons J65-Q74.

men, non-ischæmic preservation with continuous perfusion and control of post-transplantation growth of the transplant<sup>1</sup>. Here, for the first time, we show that the use of organs from PCMV/PRV-positive pigs in this life-supporting model is associated with a reduction of the transplant survival time.

Our data on reduction of the survival time of PCMV/PRV-positive pig hearts orthotopically transplanted into baboons supports previous findings in other preclinical trials on kidney xenotransplantations<sup>28,29,32–36</sup>. In these studies, PCMV/PRV was found in all organs of the baboon recipients, with the highest copy numbers in liver, lung and kidney<sup>33</sup>. An increased PCMV/PRV virus load was found in 22 different pig xenotransplants with a survival time between 7 and 32 days in baboons<sup>33</sup>. The presence of PCMV/PRV was usually found associated with consumptive coagulopathy (CC)<sup>34</sup>. However, there was no correlation between PCMV/PRV infection and CC, but lower levels of PCMV/PRV infection were always associated with a prolonged transplant survival<sup>34</sup>. When a heterotopic pig heart transplantation was performed in baboons, the survival time of the transplant was shorter when the organs were PCMV/PRV-positive (median 20 days), compared with PCMV/PRV-negative transplants (median 53 days)<sup>35</sup>. Most importantly, early weaning was shown to prevent PCMV/PRV infection of the pigs<sup>35</sup>. Organs from PCMV/PRV-free animals due to early weaning did not induce CC. Unfortunately, PCMV/PRV had been shown to have a reduced susceptibility to ganciclovir which is very effective in inhibiting HCMV<sup>36</sup>. Ganciclovir was also given to the baboons in the present study. When kidneys from GTKO pigs were transplanted into baboons, the median survival time of the kidneys from PCMV/PRV-positive animals was 14.1 days, the survival time of kidneys from PCMV/PRV-negative animals was 48.8 days and that of kidneys from PCMV/PRV-negative animals after a Caesarean delivery was 53 days<sup>28</sup>, clearly demonstrating that the transmission of PCMV/PRV reduced significantly the kidney transplant survival. A similar effect was observed, when GTKO pig kidneys were transplanted into cynomolgus monkeys. Whereas the survival time of kidneys from PCMV/PRV-free animals was 28.7 days, the presence of PCMV/PRV reduced the survival time to 9.2 days<sup>29</sup>.

The immunosuppression used in this trial is based on an induction therapy with an anti-CD20 antibody, anti-thymocyte-globulin and a monkey-specific anti-CD40 monoclonal antibody or humanized anti-CD40LPA-Sylated. During maintenance therapy methylprednisolone was reduced gradually, whereas mycophenolate mofetil and anti-CD40 monoclonal antibody or anti-CD40L PASylated Fab treatment remained constant as described in detail<sup>1</sup>. This strategy has been used successfully in other laboratories<sup>2</sup> and it was approved by the local Upper Bavarian Government. The selected immunosuppressive regimen will be easily translated into a future pig-to-human system. There are of course other immunosuppressive agents such as blocking leukocyte costimulatory molecules<sup>37</sup>, expression of CTLA4-Ig, which disrupts co-stimulatory pathways, and PD-L1, which activates T-cell inhibitory pathway<sup>38</sup>, and co-receptor blockage targeting CD4 and CD8<sup>39</sup>, however these methods have not been applied in solid organ xenotransplantation, but mainly to prevent rejection of embryonic stem cells.

Our findings that PCMV/PRV induces IL-6 and TNF release and increases the amount of tPAI-1/tPA complexes significantly contributes to the understanding of the mechanism of action of PCMV/PRV on pig transplant survival. However, there are still open questions. It is still unclear, whether PCMV/PRV can infect baboon cells. Using PCR and immunohistochemical methods, PCMV/PRV was found in all organs of the transplanted baboon (Fig. 1 and reference 27), however it is unclear whether the cells stained positive with a specific antiserum against PCMV/PRV are disseminated PCMV/PRV-producing pig cells or infected baboon cells. It is also unclear whether PCMV/PRV can infect human cells. One report claimed infection of human cells<sup>40</sup>, whereas another report showed that human cells cannot be infected with PCMV/PRV<sup>41</sup>. In our preliminary experiments incubating PBMCs from PCMV-positive pigs with human 293 cells, no infection of the human cells was observed (unpublished data). Since different non-human primate species (cynomolgus monkeys, baboons) showed a

similar reduction of the survival time (ref. 28, 29 and this study), it seems very likely that the same may happen in humans. It is important to note, that the high virus load in the recipient baboon, independent whether the virus was produced by the pig transplant or by infected baboon cells, caused rejection of the transplant mainly by acting on the cytokine production and coagulation and this cannot be analysed in a human system *in vitro*.

There are other factors which may contribute to the reduction of pig transplant survival time. A consumptive coagulopathy was often observed in non-human primates with pig xenotransplants<sup>34,42–44</sup>. Although *in vitro* an activation of the porcine tissue factor (TF) in porcine aortic endothelial cells by a PCMV/PRV infection was observed, no correlation between TF expression and PCMV/PRV infection was observed *in vivo*<sup>34</sup>. An enhanced expression of ICAM-1 (intracellular adhesion molecule I) and MHC (major histocompatibility complex) class II in the pig transplant in baboons suggests an activation of endothelial cells<sup>28</sup>. PCMV/PRV is like many other viruses immunosuppressive and was shown to modulate the expression of immune-related genes in pig immune cells<sup>22</sup>. Furthermore, a PCMV/PRV infection of pigs is usually associated with opportunistic bacterial infections on the basis of the suppressed immune system<sup>23</sup> and a transcriptome analysis of PCMV/PRV-infected thymuses showed an up- and downregulation of immune-regulatory genes<sup>24</sup>. However, considering the strong pharmaceutical immunosuppression of the animals in order to prevent rejection of the pig organ, the immunosuppressive properties of PCMV/PRV may not be important for the PCMV/PRV-induced pathogenesis.

An upregulation of IL-6 and TNF $\alpha$  in several allo- and xenotransplantation studies has previously been described indicating pathological roles for these cytokines (for review see<sup>45</sup>). IL-6 is one of the most important cytokines during an infection, along with IL-1 and TNF<sup>46</sup>. TNF is a cytokine involved in systemic inflammation and is a critical effector molecule in the immune response to viral pathogens<sup>47</sup>. TNF is able to inhibit viral replication and respond to sepsis via IL-1- and IL-6-producing cells.

The pleiotropic effects of IL-6 include the stimulation of antibody production and induction of acute-phase proteins, such as C-reactive protein (C-RP) and fibrinogen<sup>48</sup>. In a pig-to-baboon xenotransplantation study in which kidneys, hearts and artery patches from GTKO or GTKO/CD46-transgenic pigs were transplanted, significantly increased IL-6 levels were observed<sup>49</sup>. High levels of fibrinogen and C-RP positively correlated with IL-6 levels and C-RP depositions in the heart and kidney xenotransplants were detected. These data indicate that the up-regulation of IL-6 might promote systemic inflammation and together with the subsequent induction of C-RP leads to a dysregulation of coagulation after xenotransplantation<sup>49</sup>. Some studies suggest that the administration of tocilizumab, an antibody raised against the IL-6 receptor, reduced antibody-mediated rejection in post-transplantation and improved allograft survival<sup>50</sup> or reduced C-RP levels and other factors to alleviate consumptive coagulopathy<sup>51–54</sup>. Tocilizumab reacts with the human and baboon IL-6 receptor, but not with the pig IL-6 receptor<sup>54</sup>. Blocking the baboon IL-6 receptor may lead to higher circulating levels of IL-6n in the blood and this may be detrimental to pig xenotransplant survival due to IL-6 stimulation of pig cells in the transplant.

Additionally, in an *in vitro* model in which porcine aortic endothelial cells or PBMCs were incubated with human umbilical vein endothelial cells (HUVECS) an upregulation of human inflammatory cytokines including TNF $\alpha$ , chemokines and tissue factors by porcine IL-6 and TNF $\alpha$  was observed. These data indicate that porcine IL-6 and TNF $\alpha$  can stimulate recipient cells and thereby promote coagulation as well as inflammation upon xenotransplantation<sup>55</sup>. Besides IL-6 also TNF $\alpha$  was reported to be up-regulated in baboons after pig heart transplantation and seems to act as a key pro-inflammatory cytokine in xenotransplant rejection<sup>56,57</sup>. TNF $\alpha$  was also detected during acute rejection in porcine islets transplanted into non-human primates NHPs<sup>58</sup>. Furthermore, the TNF $\alpha$  antagonist etanercept was shown to suppress coagulation dysfunction in xenotransplantation and to contribute to pig kidney survival in baboons<sup>59</sup>.

Cytokines released by immune cells can also directly influence the proliferation cardiomyocytes. Whereas murine Treg cells promote proliferation of murine neonatal cardiomyocytes through paracrine factors including cytokines<sup>80</sup>, TNF $\alpha$ , IFN $\alpha$  and IL-17A produced by CD4<sup>+</sup> Th1 and Th17 cells reduced the number of cultured murine cardiomyocytes<sup>61</sup>. Therefore these cells directly inhibited proliferation and promoted the apoptosis of neonatal mouse cardiomyocytes.

Despite the seemingly overwhelming evidence for the role of PCMV/PRV, there may also be other factors contributing to the reduced survival rates. As explained elsewhere in detail<sup>1</sup>, xenotransplantation experiments in groups I and II failed because of insufficient organ preservation and overgrowth of the transplant, respectively. Baboons P and Q (group III) were euthanized because of beginning multi-organ failure, which might be attributed to other causes than PCMV/PRV: Baboon P had received a graft of borderline small size and baboon Q developed recurrent pericardial effusions. Relative size mismatch may lead to systolic heart failure, whereas recurrent effusions may lead to pericardial tamponade and diastolic insufficiency, both eventually causing multi-organ failure. Microbial translocation and opportunistic infections were observed in animals P and Q; both are common after infection with immunosuppressive viruses including human immunodeficiency virus (HIV)<sup>44</sup>, but can also be attributed to immunosuppressive treatment by itself.

It was clearly shown that PCMV/PRV replicates in the transplanted heart (Fig. 1, Table 1). Already at day three an increase of the copy number in the heart was observed, reaching much higher copy numbers later. It may be suggested that the pharmaceutical immunosuppression given to prevent rejection and possibly the PCMV/PRV-induced immunosuppression plays an important role in allowing increased PCMV/PRV replication. For comparison, previous studies of the replication rate of HCMV in humans showed that its dynamics are rapid, with a doubling time of viraemia of approximately 1 day<sup>63</sup>. In analogy to the HCMV infection, where a clear threshold relationship was observed, e.g., the virus causes disease once a threshold value of viral load is exceeded<sup>11</sup>, such a threshold seems also important in the case of PCMV. In this context, a viral load of 2 to 3 million copies may be tolerable until day 30–40, whereas higher viral loads further reduce the survival time.

Since other viruses could also interfere with the survival time of the transplants, activation of BaCMV in the transplanted baboon and transmission of HEV, PERV, PCV1, PCV2, as well as PLHV1, 2 and 3 was analysed. All baboons used in these investigations carried BaCMV, which is common in baboons. In one case a strong



activation of BaCMV after transplantation of a PCMV-positive pig heart was observed (baboon I)<sup>27</sup>. In all other cases a direct activation of BaCMV could not be observed. Concerning BaCMV activation, in another preclinical trial transplanting pig kidneys into baboons, it was also observed in control animals without transplantation, but with the corresponding immunosuppression, indicating that immunosuppression alone is able to activate BaCMV<sup>64</sup>.

HEV, genotype 3, is a well-known zoonotic virus, it is frequently transmitted to humans by undercooked meat or contact, but also by manure-contaminated fruits and water, and it induces chronic infection in immunosuppressed patients and severe liver disease in patients with an underlying liver failure<sup>65</sup>. However, until now no HEV transmission was reported in all preclinical and clinical xenotransplantation trials, including this study (Table 2).

PERV DNA was observed in the circulation of baboons following transplantation of a pig heart (Table 2). However, this observation appears to be due to circulating DNA from dead transplant cells or persistent pig cell microchimerism.

PCV1 and PCV2 were not present in the donor pigs and, logically, could not be transmitted to the recipients. Meanwhile it was published, that four donor pigs (animals 5803, 5807, 6249, 6253) were infected with PCV3 and that this virus was transmitted in all four cases to the baboon recipients (baboons O, N, P, Q)<sup>66</sup>. PCV3 is a newly described member of the virus family *Circoviridae*, it is highly distributed among farms pigs and wild boars worldwide (for review see Reference 67). Similarly to the situation with PCV2, PCV3 was found in healthy animals as well as in animals suffering from different diseases, suggesting that coinfections with other viruses are necessary for the pathogenic potential. PCV3 does not seem to influence the survival time because baboons with the highest survival time (animal N—182 days, O—195 days) and animals with low survival times (P—15 days, Q—27 days) were infected with PCV3. In contrast, there was a clear correlation between the infection with PCMV and survival (15 and 27 days versus 182 and 195 days).

Although all donor pigs were infected with PLHV-1 and PLHV-2, no transmission to the baboon recipients was observed, PLHV-3 was not found in the donor pigs. PLHV-1, -2, and -3 belong to the subfamily Gamma-herpesvirinae in the Herpesviridae family. The pathogenicity of PLHV in pigs under natural conditions is still unclear. Under experimental conditions PLHV-1 is associated with post-transplant lymphoproliferative disease (PTLD) in miniature pigs following allogeneic haematopoietic stem cell transplantation<sup>68,69</sup>. The clinical symptoms of experimental porcine PTLD, such as fever, lethargy, anorexia, high white blood cell count and palpable lymph nodes, are similar to those of human PTLD, a serious complication of solid organ and allogeneic bone marrow transplantation, which was linked to a human gammaherpesvirus, Epstein-Barr virus (human herpes virus-4, HHV-4)<sup>70</sup>.

In order to prevent transmission of porcine viruses after xenotransplantation, elimination programs had been proposed which are based on selection and isolation of virus-negative animals, vaccination or treatment with an effective antiviral drug (both are not available in the case of PCMV/PRV), early weaning, colostrum deprivation, Caesarean delivery or embryo transfer. Although PCMV/PRV can be transmitted via placenta<sup>71,72</sup>, successful elimination can be achieved by early weaning<sup>35,73</sup>, providing virus-free animals for a safe xenotransplantation.

## Methods

**Animals and transplantations.** All details of the donor pigs, the baboon recipients and the transplantation procedures were described in reference 1.

**Immunosuppression.** All baboon recipients received an immunosuppression including an induction therapy with an anti-CD20 antibody, anti-thymocyte-globulin and a monkey-specific anti-CD40 monoclonal antibody or humanized anti-CD40LPASylated as described in detail<sup>1</sup>. The group III baboon recipients analysed here were weaned from cortisone at an early stage and received antihypertensive treatment. In addition, a temsrolimus medication was applied.

**Plasma and blood collection.** Blood sampling from adult sows was performed without sedation under manual fixation. Whole blood was drawn from the jugular vein with single-use needles (Ehrhardt Medizinprodukte, Geislingen, Germany) into lithium heparin and serum Monovettes (Sarstedt, Nümbrecht, Germany). Blood from the baboons was taken using a central venous catheter.

**Ethics statement.** Both the generation of transgenic animals, as well as interventions on re-cloned animals, were performed with permission of the local regulatory authority. Applications were reviewed by the ethics committee according to §15 TSchG German Animal Welfare Act. The xenotransplantation experiment was approved by the Government of Upper Bavaria, Munich, Germany. Housing, feeding, environmental enrichment, and steps taken to minimise suffering, including the use of anaesthesia and method of sacrifice, was in accordance with the recommendations of the Weatherall report “The use of non-human primates in research”.

**Testing for PCMV/PRV.** PCMV/PRV testing was performed as described<sup>25</sup> using specific primers (Table 3). Briefly, DNA was extracted from sera, blood and organs of the pigs using the DNeasy Blood & Tissue kit (Qia-Gen GmbH, Hilden, Germany). DNA was quantified using a NanoDrop ND-1000 (Thermo Fisher Scientific Inc., Worcester, MA, USA). To screen for PCMV, a real-time PCR using described primers<sup>26</sup> and the SensiFast probe no ROX kit was performed according to supplier recommendations (Bioline GmbH, Germany). DNA from formalin-fixed tissues was extracted by using the QIAamp DNA FFPE Tissue Kit (QIAGEN), following the manufacturer’s instructions. As the starting material was not paraffin-embedded but only formalin-fixed tissue, we started the process by cutting the tissue into small pieces, added buffer and proteinase and followed the manufacturer’s protocol by incubating at 56 °C. A detection limit of 20 copies was determined for the reported

Primers Used for PCR	Sequence 5'-3'	Nucleotide position	Accession number	References
<b>Primers used for PCR</b>				
PLHV-1,-2 (747) fw PLHV-1,-2 (747) rev	CAYGGTAGTATTTATTTCAGACA GATATCCTGGTACATTGGAAG	21,146–21,167 21,488–21,467	AY170317.1	Ehlers <sup>81</sup>
PLHV-3 (905) fw PLHV-3 (905) rev	ACAAGAGCCTTAGGGTTCCAAACT GTGTCCAGTGTGTAATGGATGCC	13,472–13,495 13,727–13,704	AY170316.1	Chmielewicz et al. <sup>82</sup>
PCV1 fw (F41) PCV1 rev (B42)	ATACGGTAGTATTGGAAGGTAGGG ACACTCGATAAGTATGTGGCCTTCT			Mankertz et al. <sup>84</sup>
PCV2 fw (F66) PCV2 rev (B67)	GGTTTGTAGCCTCAGCCAAAGC GCACCTTCGGATATACTGTCAAGG	567–546 152–175	KT868491.1	Mankertz et al. <sup>66</sup>
PERV env C fw PERV env C rev	CTGACCTGGATTAGAACTGG ATGTTAGAGGATGGTCCTGG	6606–6625 6867–6886	AM229312	Takeuchi et al. <sup>74</sup>
<b>Primers and probes used for real-time PCR</b>				
pGAPDH fw pGAPDH rev pGAPDH probe	ACATGGCCTCCAAGGAGTAAGA GATCGAGTTGGGGCTGTGACT HEX-CCACCAACCCAGCAAGAGCA CGC-BHQ1	1083–1104 1188–1168 1114–1137	NM_001206359.1	Duvigneau et al. <sup>85</sup>
JVHEVF JVHEV/JVHEVProbe	GGTGGTTTCTGGGGTGAC AGGGGTTGGTTGGATGAA FAM-TGATTCTCAGCCCTTCGC-BHQ	5261–5278 5330–5313 5284–5301	M73218	Jothikumar et al. <sup>60</sup>
PCMV fw PCMV rev PCMV probe	ACTTCGTCGCAGCTCATCTGA GTTCTGGGATCCGAGGTTG 6FAM-CAGGGCGGCGGTGAGCT C-BHQ!	45206–45226 45268–45249 45247–45229		Mueller et al. <sup>33</sup>
BaCMV real fw BaCMV real rev BaCMV probe	GTTTAGGGAACCGCCATTCTG GTATCCGCGTTCCAATGCA 6FAM-TCCAGCCTCCATAGCCGG GAAGG-BBQ			Mueller et al. <sup>32</sup>
huGAPDH fw huGAPDH rev huGAPDH probe	GGCGATGCTGGCGCTGAGTAC TGGTCCACACCCATGACGA HEX-TTCACCACCATGGAGAAGGCT GGG-BHQ1	3568–3587 3803–3783 3655–3678	AF261085	Behrendt et al. <sup>86</sup>
PERV Pol fw PERV Pol rev PERV Pol probe	CGACTGCCCAAGGGTTCAA TCTCTCTGCAAATCTGGGCC 6FAM-CACGTACTGGAGGAGGGTCAC CTG-BHQ1		HM159246	Yang et al. <sup>8</sup>

**Table 3.** Primers and probes.

PCR method<sup>26</sup>. Various amounts (25–250 ng) of DNA were used for testing. The reaction mixture contained 300 nM of both primers, and 250 nM of the probe (Table 3) in a final volume of 20  $\mu$ L. The following conditions for amplification were used: denaturation at 95 °C for 5 min, and 45 cycles of amplification with denaturation at 95 °C for 15 s, annealing at 56 °C for 30 s and extension at 72 °C for 30 s. Reporter fluorescence was measured using the CFX96 Toich Real-time PCR detection system (Bio-Rad, Hercules, CA, USA).

**Testing for BaCMV.** To test for BaCMV, a real-time PCR was performed using described primers<sup>32</sup> (Table 3), but the enzymes and conditions had been changed: Denaturation at 95 °C for 5 min, and 45 cycles of amplification with denaturation at 95 °C for 15 s, annealing at 57 °C for 30 s and extension at 72 °C for 30 s.

**Testing for PERV.** To test for PERV, a PCR was performed using primers for the pol sequence (Table 3) as described<sup>4</sup>. This PCR detects PERV-A, PERV-B and PERV-C, since the pol region is highly conserved. To test for PERV-C, a PCR was performed using primers specific for the env region of PERV-C (Table 3)<sup>74,75</sup>. A Western blot analysis was performed using recombinant p27Gag protein, p15E protein and gp70 protein as well as goat sera against these recombinant proteins as positive control as described<sup>4,76</sup>.

**Testing for HEV.** To test for HEV, a real-time PCR was performed as described<sup>77</sup> using specific primers<sup>78</sup>. Western blot analysis was performed using two overlapping recombinant ORF2 proteins of HEV genotype 3 as described<sup>77</sup>. One protein contained the immunodominant epitope (GT3-Ctr, aa 326–608, 32 kb)<sup>79</sup>, the other was with a glutathione-S-transferase tag (aa452–617, 44.5 kb, Orosperc, Ness Ziona, Israel).

**Testing for PLHV.** To test for PLHV-1, PLHV-2 and PLHV-3 two PCR methods and specific primers (Table 3) were used as described<sup>80–82</sup>.

**Testing for PCV.** To test for PCV1 and PCV2, a PCR method and specific primers (Table 3) were used as described<sup>63</sup>, using specific primers<sup>83</sup>.

**Measurement of cytokines.** IL-6 release over time was studied in the Laboratoriumsmedizin of the Munich University using an ELISA (Roche, Elecsys IL-6).

The BD™ CBA Non-Human Primate (NHP) Th1/Th2 Cytokine Kit (BD Biosciences, Heidelberg) was used to measure IL-2, IL-4, IL-5, IL-6, TNF and IFN  $\gamma$  in baboon serum samples according to the manufacturer's instructions. Serum samples were diluted 1:20 before use. Samples were acquired by use of a LSR II cytometer (BD Biosciences). To measure IL-10 serum levels the IL-10 Monkey ELISA Kit (Thermo Fisher, Waltham) was used according to the manufacturer's instructions.

**Measurement of coagulation.** The PAI-1/tPA complexes were measured in baboon EDTA plasma samples by a commercial ELISA kit for the measurement of human PAI-1/tPA complexes (Abcam, ab192151, <https://www.abcam.com/human-pai1tpa-elisa-kit-ab192151.html>).

**Tissue processing and histological staining.** All myocardial specimens were fixed in 4% neutral-buffered formalin and embedded in paraffin. Tissue sections were then stained with hematoxylin and eosin.

**Western blot analysis.** To detect antibodies against PERV in baboons, recombinant surface envelope protein gp70, transmembrane envelope protein p15E and core protein p27 were used as described<sup>4,76</sup>. As control goat antisera against these recombinant proteins were used. Secondary anti-goat IgG and anti-human antibodies were used and the assay was developed using alkaline phosphatase. To detect antibodies against HEV in pigs and baboons, a recombinant genotype 3 (GT3) ORF 2 core antigen<sup>61</sup> and a recombinant 44.5 kDa protein with a glutathione-S transferase (GST) tag fused to the ORF2 fragment (Prospec, Ness Ziona, Israel) was used<sup>77</sup>. Alkaline phosphatase conjugated antibodies were used and the reaction was developed using NBT (nitro-blue tetrazolium chloride)-BCIP (5-bromo-4-chloro-3'-indolylphosphate p-toluidine salt) substrate.

### Data availability

The data that support the findings reported herein are available on reasonable request from the corresponding author.

Received: 11 May 2020; Accepted: 9 September 2020

Published online: 16 October 2020

### References

- Längin, M., Mayr, T., Reichart, B., Michel, S., Buchholz, S., Guethoff, S., Dashkevich, A., Baehr, A., Egerer, S., Bauer, A., Mihalj, M., Panelli, A., Issl, L., Ying, J., Fresch, A. K., Buttgerit, I., Mokolke, M., Radan, J., Werner, F., Lutzmann, I., Steen, S., Sjöberg, T., Paskevicius, A., Qiuming, L., Sfriso, R., Rieben, R., Dahlhoff, M., Kessler, B., Kemter, E., Klett, K., Hinkel, R., Kupatt, C., Falkenau, A., Reu, S., Ellgass, R., Herzog, R., Binder, U., Wich, G., Skerra, A., Ayares, D., Kind, A., Schönmann, U., Kaup, F. J., Hagl, C., Wolf, E., Klymiuk, N., Brenner, P. & Abicht, J. M. Consistent success in life-supporting porcine cardiac xenotransplantation. *Nature* **564**(7736), 430–433 (2018).
- Denner, J. & Tönjes, R. R. Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses. *Clin Microbiol Rev.* **25**(2), 318–343 (2012).
- Wynyard, S., Nathu, D., Garkavenko, O., Denner, J. & Elliott, R. Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand. *Xenotransplantation* **21**(4), 309–323 (2014).
- Morozov, V. A. *et al.* No PERV transmission during a clinical trial of pig islet cell transplantation. *Virus Res.* **227**, 34–40 (2017).
- Harrison, I., Takeuchi, Y., Bartosch, B. & Stoye, J. P. Determinants of high titer in recombinant porcine endogenous retroviruses. *J. Virol.* **78**(24), 13871–13879 (2004).
- Denner, J., Specke, V., Thiesen, U., Karlas, A. & Kurth, R. Genetic alterations of the long terminal repeat of an ecotropic porcine endogenous retrovirus during passage in human cells. *Virology* **314**(1), 125–133 (2003).
- Niu, D. *et al.* (2017) Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. *Science* **357**(6357), 1303–1307 (2017).
- Yang, L. *et al.* Genome-wide inactivation of porcine endogenous retroviruses (PERVs). *Science* **350**(6264), 1101–1104 (2015).
- Scobie, L., Denner, J. & Schuurman, H. J. Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9, editorial commentary. *Xenotransplantation*. **24**(6) (2017).
- Denner, J. Xenotransplantation and porcine cytomegalovirus. *Xenotransplantation* **22**(5), 329–335 (2015).
- Griffiths, P., Baraniak, I. & Reeves, M. The pathogenesis of human cytomegalovirus. *J. Pathol.* **235**(2), 288–297 (2015).
- Goodman, A. L., Murray, C. D., Watkins, J., Griffiths, P. D. & Webster, D. P. CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis. *Eur. J. Clin. Microbiol. Infect. Dis.* **34**(1), 13–18 (2015).
- Gu, W. *et al.* Genomic organization and molecular characterization of porcine cytomegalovirus. *Virology* **460–461**, 165–172 (2014).
- Denner, J., Bigley, T. M., Phan, T. L., Zimmermann, C., Zhou, X. & Kaufner, B. B. Comparative analysis of roseoloviruses in humans, pigs, mice, and other species. *Viruses*. **11**(12), (2019).
- [https://talk.ictvonline.org/taxonomy/p/taxonomy-history?taxnode\\_id=20150912&taxa\\_name=Suid%20betaherpesvirus%202](https://talk.ictvonline.org/taxonomy/p/taxonomy-history?taxnode_id=20150912&taxa_name=Suid%20betaherpesvirus%202)
- Rogers, J. *et al.* Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. *Transplantation* **69**(12), 2566–2573 (2000).
- Knox, K. K., Brewer, J. H., Henry, J. M., Harrington, D. J. & Carrigan, D. R. Human herpesvirus 6 and multiple sclerosis: systemic active infections in patients with early disease. *Clin. Infect. Dis.* **31**(4), 894–903 (2000).
- Readhead, B. *et al.* Multiscale analysis of independent Alzheimer's Cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus. *Neuron* **99**(1), 64–82.e7 (2018).
- Eliassen, E. *et al.* Human herpesvirus 6 and malignancy: a review. *Front. Oncol.* **8**, 512 (2018).
- Emery, V. C. *et al.* Interactions between beta-herpesviruses and human immunodeficiency virus in vivo: evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6. *J. Med. Virol.* **57**(3), 278–282 (1999).
- Lusso, P. *et al.* Human herpesvirus 6A accelerates AIDS progression in macaques. *Proc. Natl. Acad. Sci. USA* **104**(12), 5067–5072 (2007).
- Liu, X., Liao, S., Zhu, L., Xu, Z. & Zhou, Y. Molecular epidemiology of porcine cytomegalovirus (PCMV) in Sichuan province, China: 2010–2013. *PLoS ONE* **8**, e64648 (2013).
- Edington, N., Broad, S., Wrathall, A. E. & Done, J. T. Superinfection with porcine cytomegalovirus initiate infection. *Vet. Microbiol.* **16**, 189–193 (1988).

24. Liu, X., Xu, Z., Zhu, L., Liao, S. & Guo, W. Transcriptome analysis of porcine thymus following porcine cytomegalovirus infection. *PLoS ONE* **9**(11), e113921 (2014).
25. Patel, S. J., Zhao, G., Penna, V. R., Park, E., Lauron, E. J., Harvey, I. B., Beatty, W. L., Plougastel-Douglas, B., Poursine-Laurent, J., Fremont, D. H., Wang, D. & Yokoyama, W. M. A murine herpesvirus closely related to ubiquitous human herpesviruses causes T-cell depletion. *J. Virol.* **91**(9) (2017).
26. Morozov, V. A. *et al.* Active Replication of Porcine Cytomegalovirus (PCMV) following transplantation of a pig heart into a baboon despite undetected virus in the donor pig. *Ann. Virol. Res.* **2**(3), 1018 (2016).
27. Fiebig, U., Abicht, J. M., Mayr, T., Längin, M., Bähr, A., Guethoff, S., Falkenau, A., Wolf, E., Reichart, B., Shibahara, T. & Denner, J. Distribution of porcine cytomegalovirus in infected donor pigs and in baboon recipients of pig heart transplantation. *Viruses* **10**(2) (2018).
28. Yamada, K. *et al.* Porcine cytomegalovirus infection is associated with early rejection of kidney grafts in a pig to baboon xenotransplantation model. *Transplantation* **98**(4), 411–418 (2014).
29. Sekijima, M. *et al.* Results of life-supporting galactosyltransferase knockout kidneys in cynomolgus monkeys using two different sources of galactosyltransferase knockout swine. *Transplantation* **98**, 419–426 (2014).
30. Denner, J. Reduction of the survival time of pig xenotransplants by porcine cytomegalovirus. *Virol. J.* **15**(1), 171 (2018).
31. Bongoni, A. K. *et al.* Transgenic expression of human CD46 on porcine endothelium: effect on coagulation and fibrinolytic cascades during ex vivo human-to-pig limb xenoperfusions. *Transplantation* **99**(10), 2061–2069 (2015).
32. Mueller, N. J. *et al.* Activation of cytomegalovirus in pig-to-primate organ xenotransplantation. *J. Virol.* **76**(10), 4734–4740 (2002).
33. Mueller, N. J. *et al.* Activation of porcine cytomegalovirus, but not porcine lymphotropic herpesvirus, in pig-to-baboon xenotransplantation. *J. Infect. Dis.* **189**(9), 1628–1633 (2004).
34. Gollackner, B. *et al.* Porcine cytomegalovirus and coagulopathy in pig-to-primate xenotransplantation. *Transplantation* **75**(11), 1841–1847 (2003).
35. Mueller, N. J. *et al.* Reduction of consumptive coagulopathy using porcine cytomegalovirus-free cardiac porcine grafts in pig-to-primate xenotransplantation. *Transplantation* **78**(10), 1449–1453 (2004).
36. Mueller, N. J. *et al.* Reduced efficacy of ganciclovir against porcine and baboon cytomegalovirus in pig-to-baboon xenotransplantation. *Am. J. Transplant.* **3**(9), 1057–1064 (2003).
37. Pearl, J. I. *et al.* Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. *Cell Stem Cell* **8**(3), 309–317 (2011).
38. Rong, Z. *et al.* An effective approach to prevent immune rejection of human ESC-derived allografts. *Cell Stem Cell* **14**(1), 121–130 (2014).
39. Li, J. *et al.* Coreceptor blockade targeting CD4 and CD8 allows acceptance of allogeneic human pluripotent stem cell grafts in humanized mice. *Biomaterials* **248**, 120013 (2020).
40. Whitteker, J. L., Dudani, A. K. & Tackaberry, E. S. Human fibroblasts are permissive for porcine cytomegalovirus in vitro. *Transplantation* **86**(1), 155–162 (2008).
41. Tucker, A. W., Galbraith, D., McEwan, P. & Onions, D. Evaluation of porcine cytomegalovirus as a potential zoonotic agent in Xenotransplantation. *Transplantation Proc.* **31**, 915 (1999).
42. Bühler, L. *et al.* Pig kidney transplantation in baboons: anti-Gal(alpha)1–3Gal IgM alone is associated with acute humoral xenograft rejection and disseminated intravascular coagulation. *Transplantation* **72**(11), 1743–1752 (2001).
43. Ierino, F. L. *et al.* Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts. *Transplantation* **66**(11), 1439–1450 (1998).
44. Bühler, L. *et al.* Coagulation and thrombotic disorders associated with pig organ and hematopoietic cell transplantation in nonhuman primates. *Transplantation* **70**(9), 1323–1331 (2000).
45. Zhao, Y. *et al.* Potential pathological role of pro-inflammatory cytokines (IL-6, TNF- $\alpha$ , and IL-17) in xenotransplantation. *Xenotransplantation* **26**(3), e12502 (2019).
46. Velazquez-Salinas, L., Verdugo-Rodriguez, A., Rodriguez, L. L. & Borca, M. V. The role of interleukin 6 during viral infections. *Front. Microbiol.* **10**, 1057 (2019).
47. Benedict, C. A. Viruses and the TNF-related cytokines, an evolving battle. *Cytokine Growth Factor Rev.* **14**(3–4), 349–357 (2003).
48. Tanaka, T. & Kishimoto, T. The biology and medical implications of interleukin-6. *Cancer Immunol. Res.* **2**(4), 288–294 (2014).
49. Ezzelarab, M. B. *et al.* Systemic inflammation in xenograft recipients precedes activation of coagulation. *Xenotransplantation* **22**(1), 32–47 (2015).
50. Choi, J. *et al.* Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. *Am. J. Transplant.* **17**(9), 2381–2389 (2017).
51. Iwase, H. *et al.* Further evidence for sustained systemic inflammation in xenograft recipients (SIXR). *Xenotransplantation* **22**(5), 399–405 (2015).
52. Iwase, H. *et al.* Therapeutic regulation of systemic inflammation in xenograft recipients. *Xenotransplantation* <https://doi.org/10.1111/xen.12296> (2017).
53. Li, T. *et al.* An investigation of extracellular histones in pig-to-baboon organ xenotransplantation. *Transplantation* **101**(10), 2330–2339 (2017).
54. Zhang, G. *et al.* Is interleukin-6 receptor blockade (tocilizumab) beneficial or detrimental to pig-to-baboon organ xenotransplantation?. *Am. J. Transplant.* **20**(4), 999–1013 (2020).
55. Gao, H. *et al.* Porcine IL-6, IL-1 $\beta$ , and TNF- $\alpha$  regulate the expression of pro-inflammatory-related genes and tissue factor in human umbilical vein endothelial cells. *Xenotransplantation* **25**(5), e12408 (2018).
56. Xu, H. *et al.* Prolonged discordant xenograft survival and delayed xenograft rejection in a pig-to-baboon orthotopic cardiac xenograft model. *J. Thorac. Cardiovasc. Surg.* **115**(6), 1342–1349 (1998).
57. Ashton-Chess, J. *et al.* Cellular participation in delayed xenograft rejection of hCD55 transgenic pig hearts by baboons. *Xenotransplantation* **10**(5), 446–453 (2003).
58. Kim, Y. H. *et al.* Application of the multiplex cytokine analysis to monitor xenogeneic immune responses to the porcine islet graft in non-human primate. *J. Korean Med. Sci.* **28**(12), 1729–1733 (2013).
59. Iwase, H. *et al.* Immunological and physiological observations in baboons with life-supporting genetically engineered pig kidney grafts. *Xenotransplantation* **24**(2), 10 (2017).
60. Li, J. *et al.* Regulatory T-cells regulate neonatal heart regeneration by potentiating cardiomyocyte proliferation in a paracrine manner. *Theranostics* **9**(15), 4324–4341 (2019).
61. Li, J. *et al.* Specific ablation of CD4+ T-cells promotes heart regeneration in juvenile mice. *Theranostics* **10**(18), 8018–8035 (2020).
62. Klatt NR, Funderburg NT, & Brenchley JM. Microbial translocation, immune activation, and HIV disease. *Trends Microbiol.* **21**(1), 6–13 (2013).
63. Emery, V. C. *et al.* Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. *J. Infect. Dis.* **185**, 1723–1728 (2002).
64. Issa, N. C. *et al.* Absence of replication of porcine endogenous retrovirus and porcine lymphotropic herpesvirus type 1 with prolonged pig cell microchimerism after pig-to-baboon xenotransplantation. *J. Virol.* **82**(24), 12441–12448 (2008).
65. Denner, J. Xenotransplantation and Hepatitis E virus. *Xenotransplantation* **22**(3), 167–173 (2015).



66. Krüger, L., Längin, M., Reichart, B., Fiebig, U., Kristiansen, Y., Prinz, C., Kessler, B., Egerer, S., Wolf, E., Abicht, J. M. & Denner, J. Transmission of porcine Circovirus 3 (PCV3) by xenotransplantation of pig hearts into baboons. *Viruses* **11**(7), (2019).
67. Klaumann, F. *et al.* Current knowledge on porcine circovirus 3 (PCV-3): a novel virus with a yet unknown impact on the swine industry. *Front. Vet. Sci.* **5**, 315 (2018).
68. Goltz, M. *et al.* Sequence analysis of the genome of porcine lymphotropic herpesvirus 1 and gene expression during posttransplant lymphoproliferative disease of pigs. *Virology* **294**(2), 383–393 (2002).
69. Huang, C. A. *et al.* Posttransplantation lymphoproliferative disease in miniature swine after allogeneic hematopoietic cell transplantation: similarity to human PTLN and association with a porcine gammaherpesvirus. *Blood* **97**(5), 1467–1473 (2001).
70. Ru, Y., Chen, J. & Wu, D. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation. *Eur. J. Haematol.* **101**(3), 283–290 (2018).
71. Morozov, V. A., Plotzki, E., Rotem, A., Barkai, U. & Denner, J. Extended microbiological characterization of Göttingen minipigs: porcine cytomegalovirus and other viruses. *Xenotransplantation* **23**(6), 490–496 (2016).
72. Edington, N., Wrathall, A. E. & Done, J. T. Porcine cytomegalovirus (PCMV) in early gestation. *Vet. Microbiol.* **17**(2), 117–128 (1988).
73. Egerer, S. *et al.* Early weaning completely eliminates porcine cytomegalovirus from a newly established pig donor facility for xenotransplantation. *Xenotransplantation* **25**(4), e12449 (2018).
74. Takeuchi, Y. *et al.* Host range and interference studies of three classes of pig endogenous retrovirus. *J. Virol.* **72**(12), 9986–9991 (1998).
75. Kaulitz, D. *et al.* Development of sensitive methods for detection of porcine endogenous retrovirus-C (PERV-C) in the genome of pigs. *J. Virol. Methods* **175**(1), 60–65 (2011).
76. Kaulitz, D. *et al.* Generation of neutralising antibodies against porcine endogenous retroviruses (PERVs). *Virology* **411**(1), 78–86 (2011).
77. Morozov, V. A. *et al.* Extended microbiological characterization of Göttingen minipigs in the context of xenotransplantation: detection and vertical transmission of hepatitis E virus. *PLoS ONE* **10**(10), e0139893 (2015).
78. Jothikumar, N., Cromeans, T. L., Robertson, B. H., Meng, X. J. & Hill, V. R. A broadly reactive one-step real-time RT-PCR assay for rapid and sensitive detection of hepatitis E virus. *J. Virol. Methods* **131**(1), 65–71 (2006).
79. Dremsek, P. *et al.* Hepatitis E virus seroprevalence of domestic pigs in Germany determined by a novel in-house and two reference ELISAs. *J. Virol. Methods* **190**(1–2), 11–16 (2013).
80. Plotzki, E., Keller, M., Ehlers, B. & Denner, J. Immunological methods for the detection of porcine lymphotropic herpesviruses (PLHV). *J. Virol. Methods* **233**, 72–77 (2016).
81. Ehlers, B. (Robert Koch Institute, Berlin, Germany). 2002. Unpublished work.
82. Chmielewicz, B. *et al.* A novel porcine gammaherpesvirus. *Virology* **308**, 317–329 (2003).
83. Heinze, J., Plotzki, E. & Denner, J. Virus safety of xenotransplantation: prevalence of porcine circovirus 2 (PCV2) in pigs. *Ann. Virol. Res.* **2**(3), 1023 (2016).
84. Mankertz, A. *et al.* Characterisation of PCV-2 isolates from Spain, Germany and France. *Virus Res.* **66**(1), 65–77 (2000).
85. Duvigneau, J. C., Hartl, R. T., Groiss, S. & Gemeiner, M. Quantitative simultaneous multiplex real-time PCR for the detection of porcine cytokines. *J. Immunol. Methods* **306**(1–2), 16–27 (2005).
86. Brehndt, R. *et al.* A neutralization assay for HIV-2 based on measurement of provirus integration by duplex real-time PCR. *J. Virol. Methods* **159**(1), 40–46 (2009).

## Acknowledgements

This research was supported by the Deutsche Forschungsgemeinschaft, TRR127.

## Author contributions

L.K. and U.F. performed the detection methods for all viruses, M.L., B.Re., M.M., J.R., T.M., P.B. and J-M.A. performed the transplantations, collected the samples for virus testing and arranged IL-6 testing. E.W. provided the multitransgenic pigs used for xenotransplantation. B.Ro. and C.S.-H. performed the cytokine analyses, A.M., F.L., and R.R. performed the coagulation studies. C.W. performed the histological investigation, J.D. planned the virological part of the study and was writing the original draft preparation, L.K., U.F., M.L., B.Ro., J-M.A., A.M., F.L., N.S., R.R., C.W., and E.W. were reviewing and editing the manuscript, J.D., B.Re., R.R. and E.W. were supervising the project; J.D., R.R., P.B., B.Re. and E.W. were responsible for funding acquisition.

## Funding

Open Access funding enabled and organized by Projekt DEAL.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41598-020-73150-9>.

**Correspondence** and requests for materials should be addressed to J.D.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020